Olympus to Build New Manufacturing Center
Japanese facility will double worldwide production capacity and include R&D hub for clinical analyzer product line
Melville, NY, July 26, 2005 - Olympus will double its capacity to produce clinical analyzers with a new manufacturing, research and development facility scheduled to open in Mishima, Japan, in 2007. The new Mishima facility, at the base of Mt. Fuji, will serve the rapidly growing worldwide market for Olympus analyzers.
"The newly designed and expanded manufacturing and R&D operation in Mishima will make it possible for Olympus to continue growing at a robust rate in the North American market," said Stephen Wasserman, Group Vice President, Diagnostic Systems Group, Olympus America Inc. "We need the additional capacity to accommodate our current and planned rapid growth. The effects of this investment are vitally important for us, and will be beneficial for our customers in the US."
In addition to increasing manufacturing levels for Olympus' diagnostic systems, the new facility, to be located at Nagaizumi, in the Shizuoka prefecture, will also incorporate a new global research and development facility. R&D efforts for the company's diagnostic instruments product line have been co-located with manufacturing since 2000.
The new three-story Mishima facility will have nearly 161,500 square feet (15,000 square meters) of floor space and is expected to cost about $35.7 million (4 billion yen). It will replace the current facility, which has been in operation since 1978.
The Olympus line of analyzers includes the AU400®, AU400e®, AU640®, AU640e®, AU2700® and AU5400® chemistry analyzers, along with the AU3000i™ immunoassay analyzer. The AU3000i system is expected to be available in the US market in early 2006. At the current time it is being previewed and is for research use only, not for use in diagnostic procedures.
About Olympus Diagnostic Systems Group
Olympus Diagnostic Systems Group provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, comprehensive patient safety systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, enhance patient safety, maximize productivity, and deliver fast, reliable results.
Olympus is a precision technology leader, designing and delivering innovative solutions in healthcare and consumer electronics worldwide.
Olympus works collaboratively with its customers and its parent company, Tokyo-based Olympus Corporation, to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:
- Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;
- Advanced clinical and research microscopes;
- Lab automation systems, chemistry-immuno and blood bank analyzers and reagents; and
- Digital and film cameras, and digital voice recorders.
In the U. S. and Canada, Olympus serves healthcare, scientific and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers efficiently, reliably, safely, and easily achieve superior results. Olympus is the leader in gastrointestinal endoscopy and clinical and educational microscopes. The company's market-leading consumer electronics business spans North and South America. For more information, visit www.olympusamerica.com.